Recercat. Dipósit de la Recerca de Catalunya
Publication
Artículo científico (JournalArticle)
The Role of Sphingolipids Metabolism in Cancer Drug Resistance
Acid ceramidase (AC); Glucosylceramide synthase (GCS); Shingolipids, Ceramidasa ácida (AC); Glucosilceramida sintasa (GCS); Esfingolípidos, Ceramidasa àcida (AC); Glucosilceramida sintasa (GCS); Esfingolípids, Drug resistance continues to be one of the major challenges to cure cancer. As research in this field evolves, it has been proposed that numerous bioactive molecules might be involved in the resistance of cancer cells to certain chemotherapeutics. One well-known group of lipids that play a major role in drug resistance are the sphingolipids. Sphingolipids are essential components of the lipid raft domains of the plasma membrane and this structural function is important for apoptosis and/or cell proliferation. Dysregulation of sphingolipids, including ceramide, sphingomyelin or sphingosine 1-phosphate, has been linked to drug resistance in different types of cancer, including breast, melanoma or colon cancer. Sphingolipid metabolism is complex, involving several lipid catabolism with the participation of key enzymes such as glucosylceramide synthase (GCS) and sphingosine kinase 1 (SPHK1). With an overview of the latest available data on this topic and its implications in cancer therapy, this review focuses on the main enzymes implicated in sphingolipids metabolism and their intermediate metabolites involved in cancer drug resistance., We thank Teresa Moline and Rosa Somoza from the VHIR. This work was supported by grants from the Instituto de Salud Carlos III (ISCIII; PI20/00556 and CP03/00101 [ML]) and CIBERONC (ML). This work was also co-financed by the European Regional Fund (ERDF) and AECC (Spanish Association of Cancer Research) (Founding Ref. GC16173720CARR [ML]). YG-M, CM, and AS-G were supported by the VHIR, iP-FIS (ISCIII) and VHIR fellowships, respectively.
Project:
ES / PE2017-2020 PI20-00556